Gemfibrozil Tablet
Product Images NDC 66267-436

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 66267-436). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

66267 436 30

The image shows a NuCare Pharmaceuticals, Inc. label for Gemfibrozil 600 mg oral tablets. The label indicates a package of 30 tablets with each capsule shaped, white, and scored, debossed with "TG" on one side and "225" on the other. It includes the NDC 66267-436-30 and states "Rx Only," with warnings to keep out of reach of children and storage instructions at controlled temperature 68-77°F.*

FDA Label Image

Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 01)

Chemical structure diagram of Gemfibrozil showing its molecular arrangement including a benzene ring substituted with methyl groups and a propanoic acid side chain.*

FDA Label Image

Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 02)

A data table titled 'Reduction in CHD Rates (events per 1000 patients) by Baseline Lipids' from the Helsinki Heart Study over 5 years. It compares incidence of cardiac events between placebo (P) and gemfibrozil tablets (G) groups across patient subcategories defined by LDL-C, HDL-C, and TG lipid levels. The table includes event counts and rate differences.*

FDA Label Image

Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 03)

A data table titled 'Table II Cardiac Events and All-Cause Mortality (events per 1000 patients)' presenting event rates during a 3.5 year open-label follow-up to the Helsinki Heart Study. It compares groups by treatment and attendance status, including placebo, gemfibrozil tablets, and no attendance, with data for cardiac events and all-cause mortality per 1000 patients.*

FDA Label Image

Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 04)

A data table titled 'Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths and All-Cause Mortality in the Helsinki Heart Study, Years 0-8.5.' It compares Gemfibrozil at study start versus placebo at study start across four categories: Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality. Columns include event counts, Gemfibrozil: Placebo hazard ratio, and confidence interval hazard ratio ranges.*

FDA Label Image

Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 05)

A table presenting adverse effects of Gemfibrozil, categorized by body system. It distinguishes between effects with probable causal relationships and those without established causality, covering general, cardiac, gastrointestinal, central nervous system, eye, genitourinary, musculoskeletal, clinical laboratory, hematopoietic, immunologic, and integumentary effects.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.